You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
At his blog, Mike the Mad Biologist writes that he has long been in favor of NIH issuing more targeted RFAs and allowing program officers more discretion in awarding grants. A fellow blogger, DrugMonkey found that under the new NIH scoring system, impact scores tend to cluster.
...and receive Daily News bulletins.
Already have a GenomeWeb or 360Dx account?Login Now.
Don't have a GenomeWeb or 360Dx account?Register for Free.
Bloomberg reports AstraZeneca may conduct another study of its candidate SARS-CoV-2 vaccine after dosing error led to higher efficacy.
The National Health Service is to conduct a trial of Grail's blood-based screening test for cancer.
In PLOS this week: somatic mutation patterns of glioblastomas among Lebanese patients, phenome-wide study using UK Biobank data, and more.
Russia says its candidate SARS-CoV-2 vaccine has a very high efficacy rate in an initial analysis of clinical trial data, according to the Financial Times.